Rallybio (RLYB) M&A announcement summary

Deal rationale and strategic fit

• The merger aims to create a leading oncology-focused biotech with a robust pipeline of next-generation therapies, leveraging expertise in small molecules and antibody-drug conjugates for cancer treatment.

• The combined entity, to operate as Avenzo Therapeutics, will focus on addressing significant unmet needs in oncology, with exclusive rights outside Greater China.

• Leadership team with deep oncology drug development experience will guide the new company.

Financial terms and conditions

• The transaction includes a $215 million oversubscribed private placement financing, funding operations into late 2028.

• Pre-transaction Rallybio equityholders will own approximately 2.8% and Avenzo equityholders (including new investors) about 97.2% of the combined company.

• Rallybio will distribute nearly all pre-closing net cash to its stockholders and issue contingent value rights (CVRs) tied to legacy asset proceeds.

Synergies and expected cost savings

• The merger brings together teams with deep oncology drug development expertise, aiming to efficiently advance four clinical-stage programs and support multiple clinical milestones and data readouts in 2027 and 2028.